Immunotherapy for colorectal cancer

Figure 1 Immunosuppression in the tumor microenvironment. Cancer cells secrete various factors such as vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-10, transforming growth factor-β (TGF-β), Fas ligand (FasL), PD1 ligand 1 (PD-L1), and indolamine-2,3-dioxygenase (IDO), all of which promote the accumulation of heterogeneous populations of cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and tolerogenic dendritic cells (DCs). These immunosuppressive cells inhibit antitumor immunity by various mechanisms, including depletion of arginine and elaboration of reactive oxygen species (ROS) and nitric oxide (NO). The tumor microenvironment promotes the accumulation of Tregs that suppress CD8+ cytotoxic T lymphocyte (CTL) function through secretion of IL-10 and TGF-β.

Figure 2 Dendritic cell vaccines. Dendritic cells (DCs) are loaded with antigens, which are taken up and degraded into peptide fragments by antigen-presenting cells such as immature DCs. DCs process tumor-derived peptides and major histocompatibility complex (MHC) class I peptides derived from DCs. They form MHC class I-peptide complexes in the endoplasmic reticulum, which are then transported to the surface of the DCs and presented to CD8+ T cells. DCs also synthesize MHC class II peptides in the endoplasmic reticulum, which are transported to the cytoplasm where MHC class II-peptide complexes are assembled with tumor-derived peptides and presented to CD4+ T cells. CD8+ T cells become cytotoxic T lymphocytes (CTLs), which destroy cancer cells through effector molecules such as perforin and granzyme B. TCR: T cell receptor.

Figure 3 Immune regulatory checkpoints in cancer immunotherapy. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD1) are two well-described co-inhibitory molecules that are expressed on naïve or memory T cells and decrease antitumor immune responses. The CTLA-4-mediated immune checkpoint is induced in T cells at the initial response to antigen (early activation phase). After the T cell receptor (TCR) is triggered by antigen encounter, CTLA-4 is transported to the surface of naïve or memory T cells. In contrast, the major role of the PD1 pathway is not at the initial T cell activation stage but rather the regulation of inflammatory responses by effector T cells that recognize antigen in peripheral tissue cells. Thus, PD-1 is highly expressed by antigen-specific cytotoxic T lymphocytes (CTLs) in malignancies and is associated with impaired T-cell function. The best-characterized signal for PD1 ligand 1 (PD-L1) induction is interferon-γ (IFN-γ), which is predominantly produced by Th1 cells. Although PD-L2 expression is limited to dendritic cells (DCs) and macrophages, PD-L1 is broadly expressed in tissues and is considered a molecular shield that protects cells from auto-reactive attack. In some tumors, PDL1 is not constitutively expressed but is induced in response to inflammatory signals that are produced by an active antitumor immune response. Loading DCs with soluble PD1 decreases their function. Therefore, antibodies can be used to block inhibitory ligand:receptor interactions by acting on tumor cells, DCs (e.g., anti-PD-L1) or T cells (e.g., anti-CTLA-4 or anti-PD1). Combining the blockade of multiple inhibitory pathways synergistically decreases T cell anergy and improves T cell responsiveness against tumors.